The signaling cascades of the Eph receptor tyrosine kinase family and the ephrin ligands have been implicated in pathological forms of angiogenesis and tumorigenesis. While initial investigations have focused on the role of this protein-protein interaction in axonal guidance, cell attachment and motility, there is now significant evidence for the overexpression and dysregulation of this interaction in numerous cancerous tissues. The key research hypothesis of this proposal is that a limited set of structural determinants are responsible for the promiscuity and selectivity of ligand recognition exhibited by the Eph receptor family, and that these structural determinants can be exploited for small molecule modulators of this interaction. The proposed research will result in a demonstrated description and characterization of the mode of binding across this large family of receptor-ligand interactions. The outcome will be translated in a discovery approach to the development of small molecule compounds that exploit these structural determinants.
Aim 1 : Evaluate structural determinants of specificity versus promiscuity in Eph receptor-ligand binding by using X-ray crystallography.
Aim 2 : Develop strategies to stabilize the flexible Eph receptor J-K loop in the ephrin-binding cleft to facilitate receptor crystallization in complex with small molecular weight chemical compounds.
Aim 3 : Characterize and improve small molecular weight chemical compounds identified in high throughput screens and virtual ligand screens for inhibitors of EphB2 and EphB4 receptor ligand binding.
The Eph receptor tyrosine kinases and their ephrin ligands are involved in tumor growth and represent an important asset of cancer targets. Defining the structural features responsible for Eph receptor ligand specificity and affinity will enable the development of new peptide and small molecules as potenfial cancer. therapeufic starting points.
|Singh, Deo R; Kanvinde, Pranjali; King, Christopher et al. (2018) The EphA2 receptor is activated through induction of distinct, ligand-dependent oligomeric structures. Commun Biol 1:15|
|Stammes, Marieke A; Prevoo, Hendrica A J M; Ter Horst, Meyke C et al. (2017) Evaluation of EphA2 and EphB4 as Targets for Image-Guided Colorectal Cancer Surgery. Int J Mol Sci 18:|
|Wu, Bainan; De, Surya K; Kulinich, Anna et al. (2017) Potent and Selective EphA4 Agonists for the Treatment of ALS. Cell Chem Biol 24:293-305|
|Singec, Ilyas; Crain, Andrew M; Hou, Junjie et al. (2016) Quantitative Analysis of Human Pluripotency and Neural Specification by In-Depth (Phospho)Proteomic Profiling. Stem Cell Reports 7:527-542|
|Pasquale, Elena B (2016) Exosomes expand the sphere of influence of Eph receptors and ephrins. J Cell Biol 214:5-7|
|Barquilla, Antonio; Lamberto, Ilaria; Noberini, Roberta et al. (2016) Protein kinase A can block EphA2 receptor-mediated cell repulsion by increasing EphA2 S897 phosphorylation. Mol Biol Cell 27:2757-70|
|Bhaskar, Archana; Tiwary, Bhupendra Nath (2016) Hypoxia inducible factor-1 alpha and multiple myeloma. Int J Adv Res (Indore) 4:706-715|
|Singh, Deo R; Pasquale, Elena B; Hristova, Kalina (2016) A small peptide promotes EphA2 kinase-dependent signaling by stabilizing EphA2 dimers. Biochim Biophys Acta 1860:1922-8|
|Bhatia, Shilpa; Hirsch, Kellen; Baig, Nimrah A et al. (2015) Effects of altered ephrin-A5 and EphA4/EphA7 expression on tumor growth in a medulloblastoma mouse model. J Hematol Oncol 8:105|
|Wu, Bainan; Wang, Si; De, Surya K et al. (2015) Design and Characterization of Novel EphA2 Agonists for Targeted Delivery of Chemotherapy to Cancer Cells. Chem Biol 22:876-887|
Showing the most recent 10 out of 47 publications